Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1052837/000110465904033988/a04-12711_110q.htm
March 2006
February 2006
December 2005
December 2005
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact: |
Ami Knoefler |
|
Senior Director |
|
Corporate Communications and Investor Relations |
|
510-284-6350 or 510-284-6605 |
Abgenix Announces Third Quarter 2004 Financial Results
FREMONT, Calif., October 26, 2004 - Abgenix, Inc. (Nasdaq:ABGX) today reported financial results for the third quarter ended September 30, 2004.
For the quarter ended September 30, 2004, the company reported a net loss of $42.4 million or $0.48 per share, compared to a net loss of $43.6 million or $0.50 per share for the same period in 2003. The company ended the quarter with $230.7 million in cash, cash equivalents and marketable securities.
Revenues for the third quarter of 2004 were $3.4 million compared to $2.0 million for the same period in 2003. Contract revenues for the quarter ended September 30, 2004 primarily consisted of fees under technology licensing agreements, including a milestone payment from Amgen for advancement of AMG 162, a XenoMouse®-derived antibody, into pivotal clinical trials for bone loss. The companys revenues generally vary from quarter to quarter.
Operating expenses for the third quarter of 2004 were $45.4 million, compared with $45.9 million for the same period of 2003. Expenses for both 2003 and 2004 included research and development costs to advance the companys clinical and preclinical stage antibody product portfolio. The majority of third quarter 2004 research and development costs related to the companys proprietary clinical products, including its lead oncology product candidate, panitumumab, and ABX 10241, an antibody for secondary hyperparathyroidism (SHPT). Included in both periods were manufacturing start-up costs related to operating the companys antibody production facility. A portion of these manufacturing costs will continue to be classified as start-up until the facility is operating closer to full utilization. The company expects these costs to vary from quarter to quarter based on the extent of manufacturing activities for antibody product candidates, including panitumumab.
-more-
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1052837/000110465904033988/a04-12711_110q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abgenix Inc.
Abgenix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2004 10-K Annual Report includes:
CIK: 1052837
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-04-033988
Submitted to the SEC: Fri Nov 05 2004 6:32:00 PM EST
Accepted by the SEC: Mon Nov 08 2004
Period: Thursday, September 30, 2004
Industry: Biological Products No Disgnostic Substances